FY2025 EPS Estimates for BioMarin Pharmaceutical Inc. Cut by Leerink Partnrs (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities researchers at Leerink Partnrs lowered their FY2025 earnings per share estimates for BioMarin Pharmaceutical in a research report issued on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will earn $1.98 per share for the year, down from their previous forecast of $2.16. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $1.85 per share. Leerink Partnrs also issued estimates for BioMarin Pharmaceutical’s FY2026 earnings at $2.37 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $646.21 million during the quarter, compared to analysts’ expectations of $639.53 million. BioMarin Pharmaceutical had a return on equity of 5.01% and a net margin of 6.93%. The firm’s revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.11 earnings per share.

Several other brokerages have also issued reports on BMRN. Cantor Fitzgerald reiterated an “overweight” rating and issued a $100.00 price objective on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Stifel Nicolaus reissued a “buy” rating and set a $101.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, December 21st. Robert W. Baird reduced their price objective on BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 30th. Piper Sandler dropped their target price on BioMarin Pharmaceutical from $115.00 to $107.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $100.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Seven equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $107.61.

BioMarin Pharmaceutical Price Performance

BioMarin Pharmaceutical stock opened at $90.07 on Thursday. The company has a current ratio of 2.51, a quick ratio of 1.57 and a debt-to-equity ratio of 0.12. The business has a 50-day moving average of $87.61 and a 200-day moving average of $89.11. BioMarin Pharmaceutical has a 1 year low of $76.02 and a 1 year high of $99.56. The firm has a market capitalization of $17.00 billion, a P/E ratio of 102.35, a PEG ratio of 1.68 and a beta of 0.31.

Insider Activity at BioMarin Pharmaceutical

In related news, insider Henry J. Fuchs sold 35,341 shares of BioMarin Pharmaceutical stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the sale, the insider now directly owns 212,117 shares in the company, valued at $18,068,126.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 2,286 shares of the business’s stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $90.00, for a total value of $205,740.00. Following the sale, the chief accounting officer now directly owns 16,156 shares in the company, valued at $1,454,040. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Henry J. Fuchs sold 35,341 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $85.18, for a total value of $3,010,346.38. Following the sale, the insider now owns 212,117 shares in the company, valued at $18,068,126.06. The disclosure for this sale can be found here. Insiders have sold a total of 103,229 shares of company stock valued at $9,062,967 over the last 90 days. Insiders own 1.84% of the company’s stock.

Institutional Trading of BioMarin Pharmaceutical

Hedge funds and other institutional investors have recently made changes to their positions in the stock. KB Financial Partners LLC grew its position in BioMarin Pharmaceutical by 51.3% during the third quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company’s stock worth $31,000 after buying an additional 118 shares in the last quarter. ICA Group Wealth Management LLC bought a new position in BioMarin Pharmaceutical during the 4th quarter valued at approximately $31,000. Acadian Asset Management LLC raised its position in BioMarin Pharmaceutical by 395.4% during the 1st quarter. Acadian Asset Management LLC now owns 431 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 344 shares during the last quarter. Castleview Partners LLC bought a new position in BioMarin Pharmaceutical during the 3rd quarter valued at approximately $35,000. Finally, MayTech Global Investments LLC bought a new position in BioMarin Pharmaceutical during the 4th quarter valued at approximately $36,000. 98.71% of the stock is currently owned by institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.